Trials / Terminated
TerminatedNCT05244070
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986403 in participants with relapsed and/or refractory chronic lymphocytic leukemia (R/R CLL) or small lymphocytic lymphoma (SLL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986403 | Specified dose on specified days |
| DRUG | Fludarabine | Specified dose on specified days |
| DRUG | Cyclophosphamide | Specified dose on specified days |
Timeline
- Start date
- 2022-09-14
- Primary completion
- 2023-05-04
- Completion
- 2023-05-04
- First posted
- 2022-02-17
- Last updated
- 2023-07-18
Locations
9 sites across 2 countries: United States, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05244070. Inclusion in this directory is not an endorsement.